Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RECORD-III: Low-dose Rivaroxaban Post-LAAO
NCT05960721Recruiting
- Sponsor
- Xijing Hospital
- Start
- Jul 2023
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of rivaroxaban in Atrial fibrillation (AFib) (2 arms), sponsored by Xijing Hospital. Primary endpoint: Rate of the composite endpoint of any death, any stroke, systemic embolism, and BARC-defined 3 or 5 bleeding events at 24 months. Started Jul 2023; status: recruiting.
02
Drugs
rivaroxaban
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT05960721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05960721.